Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1084
Abstract: Insulin aspart is a short‐acting insulin analogue that is used to control postprandial glycemia levels in diabetic patients. The aim of this clinical trial was to compare the pharmacokinetics and pharmacodynamics of GP40071 (GP‐Asp) and… read more here.
Keywords: clinical pharmacology; pharmacology; insulin aspart; hyperinsulinemic euglycemic ... See more keywords
PKPD Modeling and Simulations to Support Biosimilar Development of Biphasic Insulin Aspart 30
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1152
Abstract: This paper presents an analysis of data from a comparative study of biosimilarity in terms of pharmacokinetics and pharmacodynamics in healthy volunteers using a hyperinsulinemic euglycemic clamp for reference and test biphasic insulin aspart 30… read more here.
Keywords: modeling simulations; biphasic insulin; test; insulin aspart ... See more keywords
Pharmacological Properties of Faster-Acting Insulin Aspart
Sign Up to like & getrecommendations! Published in 2017 at "Current Diabetes Reports"
DOI: 10.1007/s11892-017-0931-y
Abstract: Purpose of ReviewFaster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacinamide and L-arginine. As this new, “ultra-rapid insulin” is available in the EU-market and Canada, the pharmacokinetic and… read more here.
Keywords: insulin; pharmacological properties; insulin aspart; faster aspart ... See more keywords
Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-017-0539-7
Abstract: We are grateful to Dr. Srinivas for his thorough review of our data. He points out potential differences in the pharmacodynamic effects of insulin preparations between healthy people and people with diabetes and discusses several… read more here.
Keywords: absorption; insulin; insulin aspart; acting insulin ... See more keywords
Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2017.11.027
Abstract: AIMS To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) before, during and after Ramadan in patients with type 2 diabetes mellitus (T2DM) who fasted during… read more here.
Keywords: efficacy safety; insulin; insulin aspart; ramadan ... See more keywords
Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
Sign Up to like & getrecommendations! Published in 2019 at "Canadian journal of diabetes"
DOI: 10.1016/j.jcjd.2019.01.004
Abstract: Limiting postprandial glucose (PPG) excursions is an important aspect of overall glycemic control. Rapid-acting insulin analogues (RAIAs) aim to mimic the physiologic action of endogenous insulin observed in individuals without diabetes and prevent excessive PPG… read more here.
Keywords: insulin; insulin analogues; type diabetes; insulin aspart ... See more keywords
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2018.1513406
Abstract: Abstract Aims: The clinical and economic impact of diabetes is growing in the US. Choosing therapies that are both effective and cost-effective is becoming increasingly important. The aim of the present analysis was to assess… read more here.
Keywords: plus insulin; glargine u100; insulin glargine; insulin aspart ... See more keywords
Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2018.1389888
Abstract: ABSTRACT Introduction: Co-formulation of basal and bolus insulin components provides a simpler regimen for patients with type 2 diabetes than separate basal–bolus treatment. However, conventional premixed insulin products include a suboptimal protaminated basal component that… read more here.
Keywords: degludec insulin; insulin; basal; japanese patients ... See more keywords
Influence of insulin collection preservatives in postmortem blood: application to a case of insulin aspart suicide.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of analytical toxicology"
DOI: 10.1093/jat/bkac094
Abstract: Insulin aspart (Novorapid ®, NovoMix®, Novolog® and Fiasp®) is a fast-acting analog of human insulin, indicated in the treatment of type I and II diabetes. It is administered before meals to mimic the physiological insulin… read more here.
Keywords: toxicology; insulin aspart; blood; collection ... See more keywords
Biosimilars and Novel Insulins.
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000001079
Abstract: BACKGROUND Insulin therapy is the mainstay of treatment for type 1 diabetes and may be necessary in type 2 diabetes. Current insulin analogues present a more physiological profile, are effective, and with less risk of… read more here.
Keywords: biosimilar insulins; insulin; insulin aspart; faster aspart ... See more keywords
Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Diabetic Medicine"
DOI: 10.1111/dme.13866
Abstract: This post hoc analysis explored whether mealtime fast‐acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin. read more here.
Keywords: aspart; mealtime fast; insulin aspart; type diabetes ... See more keywords